Danthron

Summary

Danthron (CHEMBL53418) is an approved small-molecule apoptosis inducer (ATC A06AB53); indicated across 1 condition including constipation disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A06AB53 (+1 more)
• Indications: 1 condition
• Chemistry: 240.21 Da · C14H8O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL53418
Name	Danthron
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2950
ChEBI	CHEBI:3682
ATC	A06AB53, A06AB03
Molecular formula	C14H8O4
Molecular weight	240.21
InChIKey	QBPFLULOKWLNNW-UHFFFAOYSA-N

SMILES: C1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=CC=C3O

IUPAC name: 1,8-dihydroxyanthracene-9,10-dione

ChEBI definition: A dihydroxyanthraquinone that is anthracene-9,10-dione substituted by hydroxy groups at positions 1 and 8.

Pharmacological roles (ChEBI): apoptosis inducer.

Other ChEBI roles (chemical / environmental): plant metabolite.

Also known as: Danthron, Dantron, Dantrone, Dorbane, Istizin, NSC-38626, NSC-646568, Pilules vinchy n.f., SID17389963, SID26747347, SID8139970, 1,8 Dihydroxy-anthraquinone

Patent coverage: 1,787 distinct patent families (4,229 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 3,904 (92%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 15 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Nuclear receptor ROR-gamma, Survival motor neuron protein, Prelamin-A/C, 4’-phosphopantetheinyl transferase ffp, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Amine oxidase [flavin-containing] A, Thyrotropin receptor, Amine oxidase [flavin-containing] B.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 21 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TSHR	5.7	Potency	1995	nM	CHEMBL_ACT_3911127
TSHR	5.7	Potency	1995	nM	CHEMBL_ACT_4617062
MAPK1	5.5	Potency	3162	nM	CHEMBL_ACT_4524654
MAPT	5.3	Potency	5012	nM	CHEMBL_ACT_4036128
LMNA	5	Potency	10000	nM	CHEMBL_ACT_3626272
P51450	5	Potency	10000	nM	CHEMBL_ACT_4810306

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
constipation disorder	4	MONDO:0002203	HP:0002019

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).